PL3558361T3 - Miostatyna, aktywina lub antagoniści receptora aktywiny do stosowania w leczeniu otyłości i chorób z nią powiązanych - Google Patents

Miostatyna, aktywina lub antagoniści receptora aktywiny do stosowania w leczeniu otyłości i chorób z nią powiązanych

Info

Publication number
PL3558361T3
PL3558361T3 PL17829315.5T PL17829315T PL3558361T3 PL 3558361 T3 PL3558361 T3 PL 3558361T3 PL 17829315 T PL17829315 T PL 17829315T PL 3558361 T3 PL3558361 T3 PL 3558361T3
Authority
PL
Poland
Prior art keywords
activin
myostatin
receptor antagonists
related conditions
treating obesity
Prior art date
Application number
PL17829315.5T
Other languages
English (en)
Inventor
Tania Silvia GARITO
Ronenn Roubenoff
Marjorie ZAKARIA
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3558361T3 publication Critical patent/PL3558361T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
PL17829315.5T 2016-12-21 2017-12-20 Miostatyna, aktywina lub antagoniści receptora aktywiny do stosowania w leczeniu otyłości i chorób z nią powiązanych PL3558361T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437097P 2016-12-21 2016-12-21
PCT/IB2017/058199 WO2018116201A1 (en) 2016-12-21 2017-12-20 Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions

Publications (1)

Publication Number Publication Date
PL3558361T3 true PL3558361T3 (pl) 2025-12-08

Family

ID=60972283

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17829315.5T PL3558361T3 (pl) 2016-12-21 2017-12-20 Miostatyna, aktywina lub antagoniści receptora aktywiny do stosowania w leczeniu otyłości i chorób z nią powiązanych

Country Status (24)

Country Link
US (3) US20190345251A1 (pl)
EP (2) EP3558361B1 (pl)
JP (3) JP7280825B2 (pl)
KR (2) KR20190097138A (pl)
CN (2) CN110087684B (pl)
AU (1) AU2017380844B2 (pl)
BR (1) BR112019012661A2 (pl)
CA (1) CA3042965A1 (pl)
CL (1) CL2019001683A1 (pl)
DK (1) DK3558361T3 (pl)
ES (1) ES3048908T3 (pl)
FI (1) FI3558361T3 (pl)
HR (1) HRP20251338T1 (pl)
IL (2) IL327136A (pl)
JO (1) JOP20190152A1 (pl)
LT (1) LT3558361T (pl)
MX (2) MX2019007581A (pl)
PH (1) PH12019501026A1 (pl)
PL (1) PL3558361T3 (pl)
PT (1) PT3558361T (pl)
RS (1) RS67393B1 (pl)
SI (1) SI3558361T1 (pl)
TW (2) TWI812606B (pl)
WO (1) WO2018116201A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
GB201706857D0 (en) 2017-04-28 2017-06-14 Select Res Ltd Health risk prediction tools
EA202190055A1 (ru) 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
KR20220054608A (ko) 2019-09-03 2022-05-03 노파르티스 아게 ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
DK4358995T3 (da) * 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
EP4392137A1 (en) 2021-08-27 2024-07-03 Versanis Bio, Inc. Combination therapies
EP4466288A4 (en) * 2022-01-19 2026-02-25 Versanis Bio Inc ACTRII ANTIBODY-BASED TREATMENTS
EP4577301A1 (en) 2022-08-26 2025-07-02 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
IL326224A (en) 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX355042B (es) * 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) * 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
JP6472999B2 (ja) 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
JP2015525230A (ja) * 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
MX2017007519A (es) * 2014-12-08 2017-08-22 Novartis Ag Antagonistas de miostatina o activina para el tratamiento de sarcopenia.
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
US11357851B2 (en) * 2015-11-11 2022-06-14 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof

Also Published As

Publication number Publication date
RU2765288C2 (ru) 2022-01-28
JP7280825B2 (ja) 2023-05-24
HRP20251338T1 (hr) 2025-12-19
PH12019501026A1 (en) 2019-12-16
TW201825120A (zh) 2018-07-16
JP2020511422A (ja) 2020-04-16
LT3558361T (lt) 2025-11-25
IL267471B1 (en) 2026-04-01
JOP20190152A1 (ar) 2019-06-20
RS67393B1 (sr) 2025-11-28
IL267471B2 (en) 2026-08-01
AU2017380844B2 (en) 2024-12-19
EP3558361A1 (en) 2019-10-30
CN110087684B (zh) 2023-12-01
JP2026116913A (ja) 2026-07-14
CL2019001683A1 (es) 2019-09-13
MX2024001135A (es) 2024-02-27
US20260167729A1 (en) 2026-06-18
KR20240147705A (ko) 2024-10-08
TWI812606B (zh) 2023-08-21
TW202417043A (zh) 2024-05-01
CA3042965A1 (en) 2018-06-28
EP4659804A3 (en) 2026-02-25
TWI848773B (zh) 2024-07-11
WO2018116201A1 (en) 2018-06-28
DK3558361T3 (da) 2025-11-03
JP2023052026A (ja) 2023-04-11
IL267471A (en) 2019-08-29
MX2019007581A (es) 2019-09-04
IL327136A (en) 2026-05-01
AU2017380844A1 (en) 2019-05-16
FI3558361T3 (fi) 2025-11-11
US20190345251A1 (en) 2019-11-14
ES3048908T3 (en) 2025-12-12
RU2019119375A3 (pl) 2021-01-29
RU2019119375A (ru) 2021-01-22
PT3558361T (pt) 2025-10-28
CN118105478A (zh) 2024-05-31
JP7843223B2 (ja) 2026-04-09
SI3558361T1 (sl) 2026-01-30
KR20190097138A (ko) 2019-08-20
EP3558361B1 (en) 2025-08-20
BR112019012661A2 (pt) 2020-01-28
CN110087684A (zh) 2019-08-02
US20210363263A1 (en) 2021-11-25
EP4659804A2 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
IL267471A (en) Myostatin, activin, or activin receptor antagonists for use in the treatment of obesity and related conditions
IL272596A (en) Pridopidine for use in the treatment of ALS
PL3227675T3 (pl) Antagoniści aktywiny-actrii i ich zastosowania w leczeniu zespołu mielodysplastycznego
IL261548B (en) 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions
IL269574A (en) Aryl hydrocarbon receptor antagonist and its uses
IL252507A0 (en) Myostatin or activin antagonists for the treatment of muscular dystrophy
IL247854A0 (en) Muscarinic receptor antagonists, preparations containing them and their uses
PL3160234T3 (pl) Kompozycie do stosowania w profilaktyce i leczeniu wzrostu biofilmu na oczach, na rękach lub stopach
SI3600415T1 (sl) Protitelo proti aktivinskemu receptorju tipa ii za uporabo pri zdravljenju srčnega popuščanja
IL271020A (en) Tinostemustine for the treatment of sarcoma
IL249020A0 (en) 1,3,4-thiadiazole compounds and their use in cancer treatment
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
PT3240520T (pt) Dispositivo de mistura e/ou de transferência
PL3154569T3 (pl) Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP
IL265066B (en) Indazole compounds for use in tendon and/or ligament injuries
PT3406258T (pt) Medicamento para utilização no tratamento de gota
GB2562583B (en) Security device
GB201404759D0 (en) Folding hand rail and bracket
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
GB201615231D0 (en) Keeping documents secure during and after delivery